Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $102.92 +0.07%
Revenue Growth %: +5.5%
Financial Fact:
Income before provision for income taxes: 22.83M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Income before provision for income taxes: 22.83M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $186.21 million.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UBS Upgrades Eaton Corporation (ETN) to Buy
- ICICI Securities Starts Jain Resource Recycling (JAINREC:IN) at Buy (1)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
